Compare
Kodiak Sciences Inc. vs C4 Therapeutics, Inc. vs Taysha Gene Therapies, Inc. vs Prime Medicine, Inc.
| Latest fiscal year | Kodiak Sciences Inc. KOD | C4 Therapeutics, Inc. CCCC | Taysha Gene Therapies, Inc. TSHA | Prime Medicine, Inc. PRME |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $35.95M | $9.77M | $4.63M |
| Revenue growth (YoY) | n/a | +1.0% | +17.3% | +55.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -320.5% | n/m | n/m |
| Net margin | n/a | -292.1% | n/m | n/m |
| Net income | -$229.97M | -$104.99M | -$109.00M | -$201.14M |
| EPS (Diluted) | -$4.32 | -$1.27 | -$0.34 | -$1.35 |
| Operating cash flow | -$136.01M | -$98.69M | -$93.09M | -$162.56M |
| Free cash flow | -$136.51M | -$99.30M | -$93.83M | -$167.09M |
| Cash & equivalents | $209.86M | $74.60M | $319.77M | $63.03M |
| Total assets | $351.53M | $359.07M | $343.32M | $342.73M |
| Total liabilities | $194.15M | $102.49M | $96.38M | $221.87M |
| Shareholders' equity | $157.38M | $256.59M | $246.94M | $120.87M |
| Return on year-end equity | -146.1% | -40.9% | -44.1% | -166.4% |
| Shares outstanding | 61.76M | 96.91M | 285.05M | 180.51M |
Revenue, most recent five fiscal years
| Fiscal year | Kodiak Sciences Inc. | C4 Therapeutics, Inc. | Taysha Gene Therapies, Inc. | Prime Medicine, Inc. |
|---|---|---|---|---|
| Latest | n/a | $35.95M Ended 2025-12-31 | $9.77M Ended 2025-12-31 | $4.63M Ended 2025-12-31 |
| 1 year earlier | n/a | $35.58M Ended 2024-12-31 | $8.33M Ended 2024-12-31 | $2.98M Ended 2024-12-31 |
| 2 years earlier | n/a | $20.76M Ended 2023-12-31 | $15.45M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $31.10M Ended 2022-12-31 | $2.50M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $45.78M Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 |